Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (16,290,695)	$ (2,171,873)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on marketable securities, net	(1,205,197)	0
Stock-based compensation expense	1,405,722	407,632
Changes in fair value of convertible debt	0	(5,424,251)
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	(641,089)	(1,200,144)
Accounts payable	848,969	565,169
Accrued expenses and other liabilities	690,290	1,289,024
Grant receivable	(1,338,827)	(915,404)
Net cash used in operating activities	(16,530,827)	(7,449,847)
Purchase of marketable securities	(48,101,129)	0
Maturities of marketable securities	19,440,000	0
Net cash used in investing activities	(28,661,129)	0
Net assets assumed in connection with reverse recapitalization	0	11,887,757
Proceeds from sale of common stock, prefunded warrants and common stock warrants	46,398,606	810,000
Payment of reverse capitalization costs	0	(1,548,643)
Net cash provided by financing activities	46,398,606	11,149,114
Net increase in cash and cash equivalents	1,206,650	3,699,267
Cash and cash equivalents at beginning of period	7,792,846	4,093,579
Cash and cash equivalents at end of period	8,999,496	7,792,846
Supplemental disclosure of non-cash financing activities:
Conversion of convertible preferred stock	0	24,287,211
Unrealized gain on marketable securities	56,197	0
Stock options granted in lieu of cash bonus	255,724	0
Cashless exercise of pre-funded warrants	945	0
Conversion of Debt into Common Stock [Member]
Supplemental disclosure of non-cash financing activities:
Conversion of convertible notes	$ 0	$ 6,989,749